#CGTDACH2026 | Pharma & Biotech
SwitzerlandSwitzerland
Feb 11 at 08:00 to Feb 12 at 18:00 CET
Overview
Advancing Scalable, Compliant & Innovative CGT Production in the DACH Region
As the Cell & Gene Therapy (CGT) industry matures, the DACH region is emerging as a critical hub for commercial manufacturing and global supply. Yet, the road from clinical promise to large-scale delivery remains paved with technical, regulatory, and supply chain challenges — particularly in viral vector capacity, closed-system adoption, and digital factory readiness.
CGT Manufacturing DACH 2026 will unite leaders from biopharma, biotech, CDMOs, regulators, and technology innovators to exchange practical solutions for scaling production, maintaining quality, and enabling global distribution.
Advancing Scalable, Compliant & Innovative CGT Production in the DACH Region
As the Cell & Gene Therapy (CGT) industry matures, the DACH region is emerging as a critical hub for commercial manufacturing and global supply. Yet, the road from clinical promise to large-scale delivery remains paved with technical, regulatory, and supply chain challenges — particularly in viral vector capacity, closed-system adoption, and digital factory readiness.
CGT Manufacturing DACH 2026 will unite leaders from biopharma, biotech, CDMOs, regulators, and technology innovators to exchange practical solutions for scaling production, maintaining quality, and enabling global distribution.
Good to know
Highlights
- 1 day 10 hours
- In-person
Refund Policy
No refunds
Location
Switzerland
Switzerland
Switzerland Switzerland
How would you like to get there?
Agenda
Unlocking Commercial Success in DACH's CGT
What's Next for Bioprocessing in CGT?
Overcoming Bottlenecks in Viral Vector Manufacturing
Organised by
IMAPAC Pte Ltd
Followers--
Events322
Hosting6 years